Oncolytic measles virus
- Proteomic Analysis Uncovers Measles Virus Protein C Interaction With p65-iASPP Protein Complex. Meignié A, Combredet C, Santolini M, Kovács IA, Douché T, Gianetto QG, Eun H, Matondo M, Jacob Y, Grailhe R, Tangy F, Komarova AV. Mol Cell Proteomics. 2021;20:100049.
- Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus. Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF. J Thorac Oncol. 2020 May;15(5):827-842.
- A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death. Delaunay T, Achard C, Grégoire M,Tangy F, Boisgerault N, Fonteneau JF. Methods Mol Biol. 2020;2058:127-132.
- Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice. Pliquet E, Ruffie C, Escande M, Thalmensi J, Najburg V, Combredet C, Bestetti T, Julithe M, Liard C, Huet T, Wain-Hobson S,Tangy F, Langlade-Demoyen P. Cancer Immunol Immunother. 2019 Apr;68(4):533-544.
- p53 regulates CD46 expression and measles virus infection in myeloma cells. Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P,Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C. Blood Adv. 2018 Dec 11;2(23):3492-3505.
- Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, Gannage M, Dréno B, Vaivode K, Pjanova D, Labarrière N, Wang Y, Chiocca EA, Boeuf FL, Bell JC, Erbs P,Tangy F, Grégoire M, Fonteneau JF. Oncoimmunology. 2017 Dec 26;7(3):e1407897.
- Nonencapsidated 5′ Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and LGP2 but Not MDA5. Mura M, Combredet C, Najburg V, Sanchez David RY,Tangy F, Komarova AV. J Virol. 2017 Sep 27;91(20). pii: e00643-17.
- Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C,Tangy F, Jouvenet N, Grégoire M, Fonteneau JF. Oncoimmunology. 2016 Nov 18;6(1):e1261240.
- Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus. Allagui F, Achard C, Panterne C, Combredet C, Labarrière N, Dréno B, Elgaaied AB, Pouliquen D,Tangy F, Fonteneau JF, Grégoire M, Boisgerault N. Curr Gene Ther. 2017;16(6):419-428.
- Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Baldo A, Galanis E,Tangy F, Herman P. Hum Vaccin Immunother. 2016 May 3;12(5):1102-16.
- Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. Achard C, Boisgerault N, Delaunay T, Roulois D, Nedellec S, Royer PJ, Pain M, Combredet C, Mesel-Lemoine M, Cellerin L, Magnan A,Tangy F, Grégoire M, Fonteneau JF. Oncotarget. 2015 Dec 29;6(42):44892-904.
- Oncolytic virotherapy for human malignant mesothelioma: recent advances. Boisgerault N, Achard C, Delaunay T, Cellerin L,Tangy F, Grégoire M, Fonteneau JF. Oncolytic Virother. 2015 Sep 10;4:133-40.
- Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Fonteneau JF, Guillerme JB,Tangy F, Grégoire M. Oncoimmunology. 2013 May 1;2(5):e24212.
- Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Boisgerault N, Guillerme JB, Pouliquen D, Mesel-Lemoine M, Achard C, Combredet C, Fonteneau JF,Tangy F, Grégoire M. Biomed Res Int. 2013;2013:387362.
- Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Guillerme JB, Boisgerault N, Roulois D, Ménager J, Combredet C,Tangy F, Fonteneau JF, Gregoire M. Clin Cancer Res. 2013 Mar 1;19(5):1147-58.
- New perspectives in cancer virotherapy: bringing the immune system into play.Boisgerault N,Tangy F, Gregoire M. Immunotherapy. 2010 Mar;2(2):185-99.
- Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Cancer Res. 2008 Jun 15;68(12):4882-92.
Recombinant measles vaccines
- A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters. Frantz PN, Barinov A, Ruffié C, Combredet C, Najburg V, de Melo GD, Larrous F, Kergoat L, Teeravechyan S, Jongkaewwattana A, Billon-Denis E, Tournier JN, Prot M, Levillayer L, Conquet L, Montagutelli X, Tichit M, Hardy D, Fernandes P, Strick-Marchand H, Di Santo J, Simon-Lorière E, Bourhy H, Tangy F. Nat Commun. 2021 Nov 1;12(1):6277.
- A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques. Nzounza P, Martin G, Dereuddre-Bosquet N, Najburg V, Gosse L, Ruffié C, Combredet C, Petitdemange C, Souquère S, Schlecht-Louf G, Moog C, Pierron G, Le Grand R, Heidmann T, Tangy F.NPJ Vaccines. 2021 Oct 22;6(1):123.
- A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Mateo M, Reynard S, Journeaux A, Germain C, Hortion J, Carnec X, Picard C, Baillet N, Borges-Cardoso V, Merabet O, Vallve A, Barron S, Jourjon O, Lacroix O, Duthey A, Dirheimer M, Jouvion G, Moreau PH, Fellmann L, Carbonnelle C, Raoul H, Tangy F, Baize S. Sci Transl Med. 2021 Jun 9;13(597):eabf6348.
- Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H,Tangy F, Baize S. Sci Transl Med. 2019 Oct 2;11(512).
- Recombinant measles vaccine expressing malaria antigens induces long-term memory and protection in mice. Mura M, Ruffié C, Combredet C, Aliprandini E, Formaglio P, Chitnis CE, Amino R,Tangy F. NPJ Vaccines. 2019 Feb 27;4:12.
- Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya. Gerke C, Frantz PN, Ramsauer K,Tangy F. Expert Rev Vaccines. 2019 Apr;18(4):393-403.
- hCD46 receptor is not required for measles vaccine Schwarz strain replication in vivo: Type-I IFN is the species barrier in mice. Mura M, Ruffié C, Billon-Denis E, Combredet C, Tournier JN,Tangy F. Virology. 2018 Nov;524:151-159.
- RIG-I Recognizes the 5′ Region of Dengue and Zika Virus Genomes. Chazal M, Beauclair G, Gracias S, Najburg V, Simon-Lorière E,Tangy F, Komarova AV, Jouvenet N. Cell Rep. 2018 Jul 10;24(2):320-328.
- Measles-derived vaccines to prevent emerging viral diseases. Frantz PN, Teeravechyan S,Tangy F. Microbes Infect. 2018 Oct – Nov;20(9-10):493-500.
- Nonencapsidated 5′ Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and LGP2 but Not MDA5. Mura M, Combredet C, Najburg V, Sanchez David RY,Tangy F, Komarova AV. J Virol. 2017 Sep 27;91(20). pii: e00643-17.
- Chikungunya Virus Vaccines: Viral Vector-Based Approaches. Ramsauer K,Tangy F. J Infect Dis. 2016 Dec 15;214(suppl 5):S500-S505.
- Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Baldo A, Galanis E,Tangy F, Herman P. Hum Vaccin Immunother. 2016 May 3;12(5):1102-16.
- Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B,Tangy F. Lancet Infect Dis. 2015 May;15(5):519-27.
- Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Escriou N, Callendret B, Lorin V, Combredet C, Marianneau P, Février M,Tangy F. Virology. 2014 Mar;452-453:32-41.
- Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. Stebbings R, Li B, Lorin C, Koutsoukos M, Février M, Mee ET, Page M, Almond N,Tangy F, Voss G. Vaccine. 2013 Dec 9;31(51):6079-86. doi: 10.1016/j.vaccine.2013.09.072.
- A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Brandler S, Ruffié C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Desprès P,Tangy F. Vaccine. 2013 Aug 12;31(36):3718-25.
- Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. Stebbings R, Février M, Li B, Lorin C, Koutsoukos M, Mee E, Rose N, Hall J, Page M, Almond N, Voss G,Tangy F. PLoS One. 2012;7(11):e50397.
- Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Lorin C, Segal L, Mols J, Morelle D, Bourguignon P, Rovira O, Mettens P, Silvano J, Dumey N, Le Goff F, Koutsoukos M, Voss G,Tangy F. Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25.
- Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. Brandler S, Marianneau P, Loth P, Lacôte S, Combredet C, Frenkiel MP, Desprès P, Contamin H,Tangy F. J Infect Dis. 2012 Jul 15;206(2):212-9.
- A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. Mourez T, Mesel-Lemoine M, Combredet C, Najburg V, Cayet N,Tangy F. Virology. 2011 Oct 25;419(2):117-25.
- Virus-host protein interactions in RNA viruses. Vidalain PO,Tangy F. Microbes Infect. 2010 Dec;12(14-15):1134-43.
- Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Desprès P,Tangy F. Vaccine. 2010 Sep 24;28(41):6730-9.
- Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Guerbois M, Moris A, Combredet C, Najburg V, Ruffié C, Février M, Cayet N, Brandler S, Schwartz O,Tangy F. Virology. 2009 May 25;388(1):191-203.
- Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Février M, Bedouelle H, Schwartz O, Desprès P, Tangy F. PLoS Negl Trop Dis. 2007 Dec 12;1(3):e96.
- Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. Desprès P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F. J Infect Dis. 2005 Jan 15;191(2):207-14.
- A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, Brahic M,Tangy F. J Virol. 2004 Jan;78(1):146-57.
- A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, Hurtrel B, McClure H, Feinberg MB, Brahic M,Tangy F. J Virol. 2003 Nov;77(21):11546-54.
